Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication

被引：15

作者：

Murphrey, Morgan ^{[1
]}

Waldman, Reid Alexander ^{[2
]}

Durso, Timothy ^{[3
]}

Grant-Kels, Jane M. ^{[4
]}

机构：

[1] Univ Calif Davis, Dept Dermatol, Davis, CA 95616 USA

[2] Dermatol Associates Glastonbury, 21 South Rd, Glastonbury, CT 06132 USA

[3] Dept Dermatol, Joint Base Andrews, MD USA

[4] Univ Connecticut, Hlth Ctr, Dept Dermatol, Farmington, CT USA

来源：

关键词：

abrocitinib; alopecia areata; atopic dermatitis; baricitinib; Janus kinase inhibitor; psoriasis; ruxolitinib; tofacitinib; upadacitinib;

D O I：

10.1016/j.jaad.2021.09.051

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：42 / 43

页数：2